KATIA HALL: Open Payments
NPI 1366865842 · CHESAPEAKE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$29,517 in 159 payments from 24 companies in 2025. Trend: 2023 $10,453 · 2024 $40,003 · 2025 $29,517
Speaker / faculty: $13,840Consulting: $9,860Food & beverage: $4,564Travel & lodging: $1,181Education: $71
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 45 | $26,104 |
| ABBVIE INC. | 18 | $482 |
| Otsuka America Pharmaceutical, Inc. | 14 | $317 |
| Teva Pharmaceuticals USA, Inc. | 11 | $299 |
| Alkermes, Inc. | 14 | $293 |
| Eisai Inc. | 2 | $245 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $244 |
| Neurocrine BioSciences, Inc. | 10 | $207 |
| Axsome Therapeutics, Inc. | 8 | $166 |
| Averitas Pharma Inc. | 1 | $150 |
Products named: SPRAVATO, VRAYLAR, ARISTADA, REXULTI, Leqembi, CAPLYTA, INGREZZA, Auvelity.
Industry payments across VA — which companies pay providers there.
